Nxera Pharma Shows Robust Q2 Growth and Progress
Company Announcements

Nxera Pharma Shows Robust Q2 Growth and Progress

Sosei Group (JP:4565) has released an update.

Nxera Pharma, formerly known as Sosei Heptares, has reported strong progress in the second quarter of 2024, including the advancement of internal clinical trials and the development of partnered programs with significant milestones. The company is poised for commercialization of PIVLAZ® in South Korea by early 2025 and anticipates a positive decision on daridorexant in Japan. Financially, revenue saw a substantial increase, primarily from PIVLAZ® sales, with research and development, as well as general and administrative expenses also rising due to increased investment and organizational strengthening.

For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Japan Auto-Generated NewsdeskNxera Pharma Gains Milestone Payment in Sleep Disorder Collaboration
TipRanks Auto-Generated NewsdeskNxera Pharma Reports Robust Revenue Growth Amid Strategic Expansion
TipRanks Japan Auto-Generated NewsdeskNxera Pharma Reports Increased Revenue but Continues to Face Losses
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App